Literature DB >> 16391039

Deoxysugar transfer during chromomycin A3 biosynthesis in Streptomyces griseus subsp. griseus: new derivatives with antitumor activity.

Nuria Menéndez1, Mohammad Nur-e-Alam, Carsten Fischer, Alfredo F Braña, José A Salas, Jürgen Rohr, Carmen Méndez.   

Abstract

Chromomycin A3 is an antitumor drug produced by Streptomyces griseus subsp. griseus. It consists of a tricyclic aglycone with two aliphatic side chains and two O-glycosidically linked saccharide chains, a disaccharide of 4-O-acetyl-D-oliose (sugar A) and 4-O-methyl-D-oliose (sugar B), and a trisaccharide of D-olivose (sugar C), D-olivose (sugar D), and 4-O-acetyl-L-chromose B (sugar E). The chromomycin gene cluster contains four glycosyltransferase genes (cmmGI, cmmGII, cmmGIII, and cmmGIV), which were independently inactivated through gene replacement, generating mutants C60GI, C10GII, C10GIII, and C10GIV. Mutants C10GIV and C10GIII produced the known compounds premithramycinone and premithramycin A1, respectively, indicating the involvement of CmmGIV and CmmGIII in the sequential transfer of sugars C and D and possibly also of sugar E of the trisaccharide chain, to the 12a position of the tetracyclic intermediate premithramycinone. Mutant C10GII produced two new tetracyclic compounds lacking the disaccharide chain at the 8 position, named prechromomycin A3 and prechromomycin A2. All three compounds accumulated by mutant C60GI were tricyclic and lacked sugar B of the disaccharide chain, and they were named prechromomycin A4, 4A-O-deacetyl-3A-O-acetyl-prechromomycin A4, and 3A-O-acetyl-prechromomycin A4. CmmGII and CmmGI are therefore responsible for the formation of the disaccharide chain by incorporating, in a sequential manner, two D-oliosyl residues to the 8 position of the biosynthetic intermediate prechromomycin A3. A biosynthetic pathway is proposed for the glycosylation events in chromomycin A3 biosynthesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16391039      PMCID: PMC1352227          DOI: 10.1128/AEM.72.1.167-177.2006

Source DB:  PubMed          Journal:  Appl Environ Microbiol        ISSN: 0099-2240            Impact factor:   4.792


  26 in total

1.  The DNA-binding drugs mithramycin and chromomycin are powerful inducers of erythroid differentiation of human K562 cells.

Authors:  N Bianchi; F Osti; C Rutigliano; F G Corradini; E Borsetti; M Tomassetti; C Mischiati; G Feriotto; R Gambari
Journal:  Br J Haematol       Date:  1999-02       Impact factor: 6.998

2.  Biosynthesis of oleandomycin by Streptomyces antibioticus: influence of nutritional conditions and development of resistance.

Authors:  C Vilches; C Méndez; C Hardisson; J A Salas
Journal:  J Gen Microbiol       Date:  1990-08

3.  Differential interactions of the Mg2+ complexes of chromomycin A3 and mithramycin with poly(dG-dC) x poly(dC-dG) and poly(dG) x poly(dC).

Authors:  S Majee; R Sen; S Guha; D Bhattacharyya; D Dasgupta
Journal:  Biochemistry       Date:  1997-02-25       Impact factor: 3.162

Review 4.  Gapped BLAST and PSI-BLAST: a new generation of protein database search programs.

Authors:  S F Altschul; T L Madden; A A Schäffer; J Zhang; Z Zhang; W Miller; D J Lipman
Journal:  Nucleic Acids Res       Date:  1997-09-01       Impact factor: 16.971

5.  Targeting of the HIV-1 long terminal repeat with chromomycin potentiates the inhibitory effects of a triplex-forming oligonucleotide on Sp1-DNA interactions and in vitro transcription.

Authors:  N Bianchi; C Rutigliano; M Passadore; M Tomassetti; L Pippo; C Mischiati; G Feriotto; R Gambari
Journal:  Biochem J       Date:  1997-09-15       Impact factor: 3.857

6.  Identification of two genes from Streptomyces argillaceus encoding glycosyltransferases involved in transfer of a disaccharide during biosynthesis of the antitumor drug mithramycin.

Authors:  E Fernández; U Weissbach; C Sánchez Reillo; A F Braña; C Méndez; J Rohr; J A Salas
Journal:  J Bacteriol       Date:  1998-09       Impact factor: 3.490

7.  New colorimetric cytotoxicity assay for anticancer-drug screening.

Authors:  P Skehan; R Storeng; D Scudiero; A Monks; J McMahon; D Vistica; J T Warren; H Bokesch; S Kenney; M R Boyd
Journal:  J Natl Cancer Inst       Date:  1990-07-04       Impact factor: 13.506

8.  Oxidative cleavage of premithramycin B is one of the last steps in the biosynthesis of the antitumor drug mithramycin.

Authors:  L Prado; E Fernández; U Weissbach; G Blanco; L M Quirós; A F Braña; C Méndez; J Rohr; J A Salas
Journal:  Chem Biol       Date:  1999-01

9.  Two glycosyltransferases and a glycosidase are involved in oleandomycin modification during its biosynthesis by Streptomyces antibioticus.

Authors:  L M Quirós; I Aguirrezabalaga; C Olano; C Méndez; J A Salas
Journal:  Mol Microbiol       Date:  1998-06       Impact factor: 3.501

10.  The sugars in chromomycin A3 stabilize the Mg(2+)-dimer complex.

Authors:  D J Silva; R Goodnow; D Kahne
Journal:  Biochemistry       Date:  1993-01-19       Impact factor: 3.162

View more
  21 in total

1.  Involvement of the beta subunit of RNA polymerase in resistance to streptolydigin and streptovaricin in the producer organisms Streptomyces lydicus and Streptomyces spectabilis.

Authors:  Marina Sánchez-Hidalgo; Luz Elena Núñez; Carmen Méndez; José A Salas
Journal:  Antimicrob Agents Chemother       Date:  2010-02-22       Impact factor: 5.191

Review 2.  Cyclization of aromatic polyketides from bacteria and fungi.

Authors:  Hui Zhou; Yanran Li; Yi Tang
Journal:  Nat Prod Rep       Date:  2010-03-31       Impact factor: 13.423

3.  Structural insight into MtmC, a bifunctional ketoreductase-methyltransferase involved in the assembly of the mithramycin trisaccharide chain.

Authors:  Jhong-Min Chen; Caixia Hou; Guojun Wang; Oleg V Tsodikov; Jürgen Rohr
Journal:  Biochemistry       Date:  2015-04-07       Impact factor: 3.162

4.  Amino acid precursor supply in the biosynthesis of the RNA polymerase inhibitor streptolydigin by Streptomyces lydicus.

Authors:  Cristina Gómez; Dina H Horna; Carlos Olano; Martina Palomino-Schätzlein; Antonio Pineda-Lucena; Rodrigo J Carbajo; Alfredo F Braña; Carmen Méndez; José A Salas
Journal:  J Bacteriol       Date:  2011-06-10       Impact factor: 3.490

5.  New Sipanmycin Analogues Generated by Combinatorial Biosynthesis and Mutasynthesis Approaches Relying on the Substrate Flexibility of Key Enzymes in the Biosynthetic Pathway.

Authors:  Mónica G Malmierca; Ignacio Pérez-Victoria; Jesús Martín; Fernando Reyes; Carmen Méndez; José A Salas; Carlos Olano
Journal:  Appl Environ Microbiol       Date:  2020-01-21       Impact factor: 4.792

6.  Biosynthesis of the RNA polymerase inhibitor streptolydigin in Streptomyces lydicus: tailoring modification of 3-methyl-aspartate.

Authors:  Dina H Horna; Cristina Gómez; Carlos Olano; Martina Palomino-Schätzlein; Antonio Pineda-Lucena; Rodrigo J Carbajo; Alfredo F Braña; Carmen Méndez; José A Salas
Journal:  J Bacteriol       Date:  2011-03-11       Impact factor: 3.490

7.  Characterization of the terminal activation step catalyzed by oxygenase CmmOIV of the chromomycin biosynthetic pathway from Streptomyces griseus.

Authors:  Mary A Bosserman; Ana B Flórez; Khaled A Shaaban; Alfredo F Braña; Jose A Salas; Carmen Méndez; Jürgen Rohr
Journal:  Biochemistry       Date:  2011-02-02       Impact factor: 3.162

Review 8.  Molecular insights on the biosynthesis of antitumour compounds by actinomycetes.

Authors:  Carlos Olano; Carmen Méndez; José A Salas
Journal:  Microb Biotechnol       Date:  2010-11-18       Impact factor: 5.813

9.  Participation of putative glycoside hydrolases SlgC1 and SlgC2 in the biosynthesis of streptolydigin in Streptomyces lydicus.

Authors:  Cristina Gómez; Dina H Horna; Carlos Olano; Carmen Méndez; José A Salas
Journal:  Microb Biotechnol       Date:  2012-06-22       Impact factor: 5.813

10.  Activation and identification of five clusters for secondary metabolites in Streptomyces albus J1074.

Authors:  Carlos Olano; Ignacio García; Aranzazu González; Miriam Rodriguez; Daniel Rozas; Julio Rubio; Marina Sánchez-Hidalgo; Alfredo F Braña; Carmen Méndez; José A Salas
Journal:  Microb Biotechnol       Date:  2014-03-04       Impact factor: 5.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.